Preliminary Scientific Program

Scientific Program is subject to change.

Welcome Notes
13:15-14:15Free Retina Papers Rapid Fire: French Papers Session
13:15-13:20Dimple in the serous pigment epithelial detachment secondary to neovascular age-related macular degeneration
Vittorio Capuano, University Paris Est Creteil, France
13:20-13:25Color fundus imaging of fibrotic scars in exudative age related macular degeneration. A comparison between Multicolor vs Color Fundus Photography vs Optos
Irene De Rosa, Centre Hospitalier Intercommunal de Créteil, France
13:25-13:30Subretinal Pigment Epithelium fibrotic tissue response to anti-Vascular Endothelial Growth Factors in Age-related Macular Degeneration
Oudy Semoun, University Paris Est Creteil, Centre Hospitalier Intercommunal de Creteil, France
13:30-13:35OCTA-guided navigated laser therapy for choroidal neovascular membranes secondary to age related macular degeneration
Francesca Amoroso, Intercity Hospital and Paris Est University, France
13:35-13:40Choroidal neovascular area and vessel density comparison between two swept-source optical coherence tomography angiography devices
Avi Ohayon, University Paris Est Creteil, Centre Hospitalier Intercommunal de Creteil, France
13:40-13:45Quantitative deep capillary plexus analysis in optical coherence tomography angiography: quiescent neovascularization versus intermediate and neovascular AMD
Donato Colantuono, Centre Hospitalier Intercommunal, France
13:45-13:50Follow up or macular neovascularization using octa: prn versus treat&extend
Pierre Sustronck, CHI Créteil, France
13:50-13:55Impact of Intravitreal Aflibercept Dosing Regimens in Treatment-Naïve Patients with Neovascular Age-Related Macular Degeneration
Marie Noelle Delyfer, CHU Hôpitaux de Bordeaux, France
13:55-14:00Comparison of modules on a mobile medical app with standard tests for remote monitoring of visual parameters
Vincent Gualino, Clinique Honoré Cave, Montauban; CHU Purpan, Toulouse; CHU Lariboisière, France
14:00-14:05Ten years Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: results of FRB France registry
Benjamin Wolff, Maison Rouge Ophthalmologic Center, Strasbourg
14:05-14:10Optical coherence tomography angiography extravascular signal in diabetic macular edema
Aude Couturier, Hôpital Lariboisière, AP-HP, Université Paris 7 – Sorbonne Paris Cité, France
14:10-14:15Real-World Use of Intravitreal Aflibercept Injections in Diabetic Macular Edema: 1-Year Interim Results of APOLLON
Catherine Creuzot Garcher, CHU Dijon, Dijon, France
14:15-16:45Clinical Cases 1
14:15-14:21OCTA Breaking News
Polina Astroz, Intercity Hospital and University Paris Est, France
14:21-14:27Watching the countryside
Eleonora Corbelli, University Vita-Salute, IRCCS Ospedale San Raffaele, Italy
14:27-14:33A matter of symmetry
Maria Vittoria Cicinelli, University Vita-Salute, IRCCS Ospedale San Raffaele, Italy
14:33-14:39Neovascularisation the choroid and CSCR
Kelvin Teo, Singapore National Eye Centre
14:39-14:45Bilateral pigmented paravenous chorioretinal atrophy
Pierre Henri Gabrielle, University Hospital, Dijon, France
14:45-14:51Anatomy versus function
Jennyfer Benillouche
14:51-14:57Mysterious cases
Wei Gui, UCLA Stein Eye Institute, USA
14:57-15:03Mysterious cases
Kirk Hou, UCLA Stein Eye Institute, USA
15:03-15:51Clinical Cases 2
15:03-15:09In need of an electrophysiologist
Olivia Zambrowski, University Paris Est Créteil, France
15:09-15:15Bilateral retrohyaloid hemorrhage complicating leukemic retinopathy: a case report
Nesma Maalej, Habib Thameur Hospital, Tunisia
15:15-15:21AMNR : differential diagnosis with PAMM. About a case in a young woman
Etephane Delage
15:21-15:27An unusual case of chrioretinitis in a young girl
Bilal Shehadeh
15:27-15:33Mysterious cases
Cameron Pole, UCLA Stein Eye Institute, USA
15:33-15:39Persistent Macular Edema in Diabetic Patient
Mark Krauthammer, Tel Aviv Medical Center, Israel
15:39-15:45Amyloid retinopathy
Vincent Daien, Guy de Chaulait Hospital, France
15:45-15:51Paraneoplasic syndrom
Sarah Tick
15:51-16:45Clinical Cases 3
15:51-15:57Treatment Dilemma of Toxic Maculopathy
Ayala Pollack, Tel Aviv Medical Center, Israel
15:57-16:03Mystery case
Sandrine Anne Zweifel, University Hospital Zurich, Switzerland
16:03-16:09Treating a Genetic Disorder with Intravitreal Corticosteroids
Richard Spaide, Vitreous Retina Macula Consultants of NY, USA
16:09-16:15A tense situation
Srinivas Sadda, Doheny Eye Institute/UCLA, USA
16:15-16:21Mystery Macula
William F. Mieler, University of Illinois at Chicago (UIC), USA
16:21-16:27Mystery case
Bailey K. Freund, Vitreous Retina Macula Consultants of New York, NYU School of Medicine, USA
16:27-16:33Mystery case
David Sarraf, Stein Eye Institute, UCLA, USA
16:33-16:39Mystery case
Eric Souied, Hôpital Intercommunal, Hopital Henri Mondor, Creteil/Universite Paris Est, France
16:39-16:45Preretinal Deposits
Caroline Baumal, Tufts University School of Medicine, USA
16:45-17:35Industry Sponsored Symposium
17:35-17:45Award Best Maculart Imaging
17:45 – 19:00Poster Session
Poster Jury: Quan Dong Nguyen-USA, Diana Do-USA, Richard Spaide-USA, Elias Reichel-USA
07:45-08:00Welcome Notes & Announcements
Moderators: Michael Singer-USA, José Sahel-France, Quan Dong Nguyen-USA
08:00-08:08The eye in space: next step to Mars travel
Thibaud Mathis, Croix-Rousse University Hospital, France
08:08-08:16Pharmacological antagonism of mineralocorticoid receptor exerts VEGF-independent anti-angiogenic effects: Implication for wet AMD
Francine Behar Cohen, Paris Descartes University, Sorbonne Paris Cité, Centre de Recherche des Cordeliers, France
08:16-08:24Imaging of RPE cells using near-infrared autofluorescence adaptive optics SLO in healthy eyes and AMD
Michel Paques,Quinze-Vingts Hospital, France
08:24-08:33Understanding effects on retinal nerve fiber layer in patients treated with  dexamethasone implants
Michael Singer, Medical Center Ophthalmology Associates, USA
08:33-08:42mTOR Inhibition for Non-Infectious Uveitis and Beyond: The Evolution of Intravitreal Sirolimus through Clinical Trials
Quan Dong Nguyen, Stanford University School of Medicine, USA
08:42-08:51Phase 1 First-In-Human Study of KSI-301: a Novel Anti-VEGF Antibody Biopolymer Conjugate with Extended Durability For Wet AMD, DME, and RVO
Diana Do, Stanford University School of Medicine, USA
08:51-09:00Photovoltaic restoration of central vision in Patients with GA
Jose Sahel, Université Pierre-et-Marie-Curie, France
09:00-09:50Macula Imaging 1
Moderators: Srinivas Sadda-USA, David Sarraf-USA, Eric Souied-France
09:00-09:08Patterns of choroidal thickness in healthy choroid : where pachychoroid does start?
Alain Gaudric, Lariboisiere Hospital, France
09:08-09:16Subretinal Pseudocyst: a novel OCT finding  in macular diseases
Giuseppe Querques,University Vita-Salute, IRCCS Ospedale San Raffaele, Italy
09:16-09:24Choriocapillaris alterations as a biomarker for predicting progression of geographic atrophy
Srinivas Sadda, Doheny Eye Institute/UCLA, USA
09:24-09:32From MNV to Fibrotic scar
Eric Souied, Hôpital Intercommunal, Hopital Henri Mondor, Creteil/Universite Paris Est, France
09:32-09:40Home OCT
Anat Lowenstein, Tel Aviv Sourasky Medical Center, Israel
09:40-09:48Chorioretinal folds associated with central serous chorioretinopathy
Salomon Yves Cohen, CIL – Centre Ophtalmologique d’Imagerie et de Laser, France
09:50-10:05Lecture: Imaging the Neurovascular Unit
Richard Spaide, Vitreous Retina Macula Consultants of NY, USA
10:35-12:00Artificial Intelligence XL Session
Moderators: Neil Bressler-USA, Pearse Keane-United Kingdom, Frank Holz-Germany
10:37-10:45What is needed to validate AI software before clinical deployment?
Adnan Tufail, NHS, United Kingdom
10:45-10:53Recent Applications of Deep Learning AI in Age-related Macular Degeneration
Neil Bressler, Wilmer Eye Institute, USA
10:53-11:01Artificial intelligence for structure-based function prediction in age-related macular degeneration
Frank Holz, University Hospital Bonn, Germany
11:01-11:09A Telemedicine Deep Learning Platform for AMD
Roland Theodore Smith, Mount Sinai School of Medicine, USA
11:09-11:17Artificial Intelligence in Ophthalmology – the Moorfields-DeepMind Collaboration
Pearse Keane, Moorfields Eye Hospital Nhs Foundation Trust, United Kingdom
11:17-11:25Prediction of individual disease conversion in early AMD using artificial intelligence
Philipp K Roberts, Medical University of Vienna, Austria
11:25-11:33Developing Human Based Intuitive Deep Machine Learning Algorithms for Analyzing Intermediate AMD OCT Images
Karl Czaky, Retina Foundation of the Southwest, USA
11:33-11:41FDA-authorized autonomous AI for diabetic retinopathy screening in clinical routine
Bianca S Gerendas, Medical University of Vienna, Austria
11:41-11:49RETINASK? MACULART! An Introduction to the (Human) Intelligence of Automated Diagnosis of Macular Disease
Samir Sayegh, The EYE Center, Champaign/Chicago, USA
11:49-11:57OphtAI – Telescreening Platform for Automatic Evaluation of Diabetic Retinopathy
Pascale G Massin, Hopital Lariboisiere, APHP, Paris 7 University, France
12:00-12:50Industry Sponsored Symposium
Moderators: Amani Fawzi-USA, Nadia Waheed-USA, Giuseppe Querques-Italy
13:45-13:53Evolution of subclinical polypoidal choroidal vasculopathy on OCTA
Gemmy Cheung Chui Ming, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
13:53-14:01AMD: Value of 3D OCT Angiography in predicting treatment frequency in neovascular AMD
Amani Fawzi, Northwestern University Feinberg School of Medicine, USA
14:01-14:09OCTA Findings and Correlations with Outcomes in Sickle Cell Retinopathy
William F. Mieler, University of Illinois at Chicago (UIC), USA
14:09-14:17Death and Destruction in the Choriocapillaris: OCTA in dry AMD
Nadia Waheed, Tufts University School of Medicine, USA
14:17-14:25Quantitative Optical Coherence Tomography Angiography biomarkers for neovascular age related macular degeneration treated using a treat-and-extend regimen
Florance Coscas,  Centre Hospitalier Intercommunal de Creteil, University Paris-Est Creteil, France
14:25-14:33Detection of Retinal Arterial (micro-)Emboli after Transcatheter Aortic Valve Implantation using OCTA and Fluorescence Angiography
Sandrine Anne Zweifel, University Hospital Zurich, Switzerland
14:33-14:41Long-term quantitative analysis of choriocapillaris flow impairment in age-related macular degeneration by means of optical coherence tomography angiography
Alexandra Miere,  Centre Hospitalier Intercommunal de Créteil, Paris XII University, France
14:45-15:45Diabetes 1
14:45-14:53Morpho-functional analysis of the retina in type 1 diabetic patients without complications after 30 years of disease
Francesco Bandello, San Raffaele Scientific Institute, Italy
14:53-15:01OCTA features of IRMA and retinal neovascularization
Caroline Baumal, Tufts University School of Medicine, USA
15:01-15:09Factors Associated With Visual Acuity and Central Subfield Thickness Outcomes with Anti-VEGF Therapy for Diabetic Macular Edema: Protocol T – DME session
Susan Bressler, Johns Hopkins University School of Medicine and Hospital, USA
15:09-15:17The Correlation of Response to Treatment with anti-VEGF compounds between the First and Second Treated Eyes in Diabetic Macular Edema
Itay Chowers, Hadassah Medical Center, Israel
15:17-15:25DRCR Protocol S:  Humphrey Visual Field Testing Data Over 5 Years
Michael Elman, Elman Retina Group, P.A., USA
15:25-15:33OCT Central Subfield Thickness and Visual Acuity in DME: Correlation, or Lack Thereof
Neil Bressler, Wilmer Eye Institute, USA
15:33-15:41Visual acuity gain profiles and anatomical prognosis factors in patients with drug-naive diabetic macular edema treated with dexamethasone implant: the NAVEDEX study
Mauricio Pinto, Croix-Rousse University Hospital, France
16:00-16:50Industry Sponsored Symposium
16:50-18:10Inherited Disorders and Gene Therapy
(Sensgene Session)
Moderators: Helene Dollfus-France, Johanna Seddon-USA, Jason Slakter-USA
16:50-16:58Genetic Therapies Beyond RPE65
Bart Leroy, Ghent University Hospital
16:58-17:06Role of Genetic testing in retinal diseases
Elise Heon, Institute of Medical Science – University of Toronto
17:06-17:14New Insights into the Genetic Basis of Macular Telangiectasia Type 2 (MacTel)
Paul Bernstein, Mary Boesche Professor of Ophthalmology and Visual Sciences, USA
17:14-17:22Is The Choroid Driving CME in Retinitis Pigmentosa?
David Sarraf, Stein Eye Institute, UCLA, USA
17:22-17:30A Composite, Polygenic Prediction Model is Validated in an External Cohort for Macular Degeneration Progression and Predictors of  Incident Advanced AMD and Visual Acuity Loss Identify High Risk Individuals
Johanna Seddon, University of Massachusetts Medical School, USA
17:30-17:38Retinal Gene Therapy for Batten’s Disease
Jason Slakter, New York University School of Medicine, USA
17:38-17:46Phenotypic characteristics of rod-cone dystrophy associated with MYO7A mutations in a Large French Cohort
Isabelle Audo, Sorbonne Université, France
17:46-17:54Design of a randomized, placebo-controlled phase one trial to evaluate the safety, pharmacokinetics and pharmacodynamics of BIO201 developed for the treatment of intermediate AMD and Stargardt Disease
Waly Dioh, Biophytis, Sorbonne Université, France
17:54-18:02Luxturna, the first approved gene therapy for RPE65-related retinal dystrophy: first European experience
Saddek Mohand Said, Sorbonne Universités, France
18:02-18:10Rare eye diseases, two examples of French & European expert networks, SENSGENE and ERN-EYE
Helene Dollfus, Sensgene, France
07:45-08:00Welcome Notes & Announcements
08:00-09:00Free Retina Papers-Rapid fire
Moderators: Mark Gilles-Australia, Kyoko Ohno-Matsui-Japan
08:00-08:05Contribution of MRI for the etiological assessment of uveitis: about 402 patients
Nicolas Chirpaz, Hospices Civils de Lyon, Croix-Rousse Hospital, France
08:05-08:10Volume rendering of central macula flow using optical coherence tomography angiography: qualitative and quantitative characterization
Ana Catarina Dias, Instituto de Oftalmologia Dr. Gama Pinto, Portugal
08:10-08:15Real-life study in diabetic macular edema treated with dexamethasone implant: a long time follow up results
Theo Lereuil, Hopital de la Croix Rousse LYON; Hospices Civils de Lyon, France
08:15-08:20AI in the real world: What are the perspectives
Amir Sadeghipour, Medical University of Vienna, Austria
08:20-08:25Subretinal OCT-A hyper reflective signal in central serous chorioretinopathy: newvessels or not ?
Martine Mauget Faÿsse, Fondation Adolphe de Rothschild, France
08:25-08:30Optical coherence tomography angiography findings in patients with PCV secondary to chronic central serous chorioretinopathy
Enrico Peiretti, University of Cagliari, Italia
08:30-08:35Setting up a nurse-led Optical Coherence Tomography (OCT) clinic: Structure and role of the clinic
Boo Hui Tan, NHS Borders, Borders General Hospital, United Kingdom
08:35-08:40Sub-retinal pigment epithelium-basal lamina hyperreflective crystalline deposits in non-neovascular age-related macular degeneration: multimodal imaging and prognostic implications
Serena Fragiotta, Vitreous Retina Macula Consultants of New York, USA
08:40-08:45Ten-year incidence and progression of diabetic retinopathy in type 1 and type 2 diabetes mellitus in France and its impact on screening strategy: the OPHDIAT study
Pascale G Massin, Hopital Lariboisiere, APHP, Paris 7 University, France
08:45-08:50Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration
Mark Gillies, The University of Sydney, Australia; Sydney Eye Hospital, Australia
08:50-08:55Visual and expanded anatomical outcomes for brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from HAWK and HARRIER
Benjamin Wolff, Maison Rouge Ophthalmologic Center, France
09:00-10:40AMD Treatments
Moderators: Lawrence Singerman-USA, Usha Chakravarthy-United Kingdom
09:00-09:08Long term outcomes in the IVAN trial
Usha Chakravarthy, Queen’s University, United Kingdom
09:08-09:16Intravitreal injection : how to prevent infection ?
Catherine Creuzot Garcher, University Hospital of Dijon, France
09:16-09:24The potential of retinal rejuvenation therapy, 2RT, as an early intervention for AMD
John Marshall, University College London, United Kingdom
09:24-09:32Gene Therapy: The Next Revolution
Pravin Dugel, Retinal Consultants of Arizona, USA
09:32-09:40Can AMD Treat Itself?
Bailey K Freund, Vitreous Retina Macula Consultants of New York, NYU School of Medicine, USA
09:40-09:48Outcomes of discontinuing VEGF inhibitors in neovascular AMD
Mark Gillies, The University of Sydney School of Medicine, Australia
09:48-09:56Phase I/IIa Clinical Trial of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigmented Epithelium (RPE, OpRegen) Transplantation in Advanced Dry Form Age-Related Macular Degeneration (AMD): Interim Results
Jordi Mones, Institut de la Macula, Spain; Barcelona Macula Foundation, Spain
09:56-10:04Brolucizumab for AMD: a reduction in the burden of treatment is likely
Lawrence Singerman, Retina Associates Of Cleveland. Inc., USA
10:04-10:12APL-2 Complement Therapy for Geographic Atrophy
Jason Slakter, New York University School of Medicine, USA
10:12-10:20Brimonidine Safety and efficacy in patients with geographic atrophy secondary to AMD
Eric Souied, Hôpital Intercommunal, Hopital Henri Mondor, Creteil/Universite Paris Est, France
10:20-10:28Evaluation of Baseline Characteristics on Lesion Progression in a Large Phase 2 Clinical Trial for Geographic Atrophy (FILLY Study)
Jordi Monés, Insitut de la Màcula, Centro Médico Teknon, Spain
10:28-10:36Brolucizumab versus aflibercept for neovascular AMD: expanded fluid analyses from the HAWK and HARRIER studies
Hessam Razavi, Transparency Eye Clinic, France
10:40-10:55LECTURE  Treating Blindness at the Nanoscale: Nanotechnologies as Treatments for Retinal Blindness
Marco Zarbin, New Jersey Medical School, USA
11:15-12:25Macular Imaging 2
Moderators: Richard Spaide-USA, Bruno Lumbroso-Italy, Salomon Yves Cohen-France
11:18-11:26What have we learned from quiescent CNV? Reflections on geographical atrophy
Alfredo Garcia Layana, The Spanish Vitreoretinal Society (SERV), Spain
11:26-11:34Hyperspectral Autofluorescence (AF) Imaging for Early Detection of Age-related Macular Degeneration (AMD)
Roland Theodore Smith, Mount Sinai School of Medicine, USA
11:34-11:42New Proposal for the Pathophysiology of Type 3 Neovascularization as Based on Multimodal Imaging Findings
Richard Spaide, Vitreous Retina Macula Consultants of NY, USA
11:42-11:50Morphology of pachychoroid neovasculopathy CNV
Bruno Lumborso, Centro Oftalmologico Mediterraneo, Italy
11:50-11:58Nonperfusion assessment in retinal vein occlusion: comparison between ultrawide-field fluorescein angiography and large-field OCT-angiography (12mmx12mm)
Agnes Glacet Bernard, Centre Hospitalier de Créteil, France
11:58-12:06Evolution of Type 1 NV and PED in AMD: En Face OCT and OCTA 3D Volumetric Analysis
David Sarraf, Stein Eye Institute, UCLA, USA
12:06-12:14Persistent plaquoid maculopathy
Alexander Brucker, Penn Medicine, USA
12:14-12:22OCT characteristics of eyes with favorable long-term visual outcomes after anti-VEGF therapy
Srinivas Sadda, Doheny Eye Institute/UCLA, USA
12:25-13:15Industry Sponsored Symposium
14:10-15:15Geographic Atrophy/Myopia/Inflammation
Moderators: Emmett Cunningham-USA, Bahram Bodaghi-France, Jordi Monés, Spain
14:10-14:18Predictors of recurrence in patients with retinochoroidal toxoplasmosis
Bahram Bodaghi, Sorbonne University, APHP, France
14:18-14:26Uveitis in the setting of common variable immune disorder
Emmett Cunningham, The Francis I. Proctor Foundation, Ucsf, USA
14:26-14:34The Rate of Progression of Geographic Atrophy Decreases With Increasing Baseline Lesion Size Even After the Square Root Transformation
Jordi Monés, Institut de la Màcula, Spain
14:34-14:42OCT-based classification of myopic maculopathy
Kyoko Ohno-Matsui, Tokyo Medical and Dental University, Japan
14:42-14:50TOGA Study: A Phase II/III Clinical Trial Evaluating Doxycycline for Geographic Atrophy
Elias Reichel, Tufts University School of Medicine, USA
14:50-14:58Risk factor for geographic atrophy in anti-VEGF treated patients
Giovanni Staurenghi, Università degli Studi di Milano, Italy
14:58-15:06Real life study in UVeitis treated with DEXamethasone implant
Laurent Kodjikian, Président de la Société Française d’Ophtalmologie (SFO), France
15:06-15:14Retinal complications of myopia: a cross-sectional study
Nicolas Leveziel, Chu (University Hospital Center) de Poitiers, France
15:15-16:00Macula Surgery
Moderators: Ramin Tadayoni, Joseph Moisseiev-Israel
15:15-15:23Vitreoschisis and diabetic vitrectomy
Mohamed Bennani, Morocco
15:23-15:31The outcome of failed pneumatic retinopexy cases
Joseph Moisseiev, Sheba Medical Centre, Israel
15:31-15:39Luxturna, the first approved gene therapy for RPE65 mutation related retinal dystrophy:: Our first surgery experience
Pierre Olivier Barale, CHNO, France
15:39-15:47Human Amniotic Membane plug to promote recurrent macular hole closure
Tomaso Caporossi, Clinica Oculistica AOU Careggi Florence, Italy
15:47-15:55Epiretinal membrane foveoschisis
Ramin Tadayoni
16:00-16:30Lecture: Pitfalls in Publishing-A Roadmap to Acceptance
Alexander Brucker, Penn Medicine, USA
16:30-18:00Retina Games Session
List of teams:
Italy :
Mavi Cicinelli
Eleonora Corbelli
Pasquale Viggiano
Eliana Costanzo
Claudio IovinoSingapore :
Sandy zhou
George Thomas
Beau Fenner

UK :
Roy Schwartz
Anjali Gupta
Emanuel De Carvalho
Israel :
Bilal Shehadeh
Muhammad Abumanhal
Mark Krauthammer

USA West Coast :
Wayne Gui
Cameron Pole
Kirk Hou

Switzerland :
Maximilian Wiest
Simon Zehnder
Timothy Haman

Morocco :
Ajdir sanae
Badreddine houmane

France :
Pierre Duraffour
Caroline Bottin
Anthony Amaral